drugset / Trial / NCT02385032

Comparative Bioavailability Study of UDCA

NCT02385032

Phase 1 Completed 50 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate bioavailability of two formulations of ursodiol.

Timeline

Start
2015-02
Primary completion
2015-03
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule

Indications

No indication recorded.